The global ultrasound-guided breast biopsy market is expected to reach USD 1,090 Million in 2032, exhibiting a CAGR of 8% during the forecast period. Ultrasound-guided biopsy market is currently valued at USD 720 Million in 2022.
Rising incidence of breast cancer cases and increasing awareness about early diagnosis of breast cancer will push sales in the market over the forecast period.
| Report Attribute | Details |
|---|---|
| Ultrasound-Guided Breast Biopsy Market Size (2022) | USD 720 million |
| Ultrasound-Guided Breast Biopsy Market Size (2032) | USD 1,090 million |
| Ultrasound-Guided Breast Biopsy Market Projected Growth Rate (2022 to 2032) | 8% CAGR |
According to a 2021 report by WHO, there were 2.3 million women diagnosed with breast cancer and 685,000 deaths, globally, in the year 2020. In 2020, 7.8 million women were living with breast cancer, making it world’s most prevalent cancer.
Breast cancer forms either with the breast tissue which is made up of glands for milk production known as lobules or begins in the ducts. These abnormalities or lumps in the breasts are generally detected with mammography, physical examinations, or other imaging techniques such as ultrasound-guided breast biopsy.
In an ultrasound-guided breast biopsy, radiologists use ultrasound imaging as a guide to inspect the site of the abnormal cell growth. A breast biopsy with the aid of ultrasound is mostly performed when an abnormality such as a distortion of the breast tissue or a suspicious mass of solid is felt around the breast.
High rate of mortality and increasing incidence of breast cancer will underpin the adoption of ultrasound-guided breast biopsy over the assessment period.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
Ultrasound-guided breast biopsy is comparatively less invasive than other surgical biopsies, it leaves little scarring and can be performed in a limited time frame. These factors, combined together, will increase the adoption rate of ultrasound-guided breast biopsy.
In addition to this, ultrasound-guided breast biopsy does not carry ionizing radiation and provides faster results. It is also less expensive and has shorter recovery period. On the back of these factors, demand in the market is projected to increase at a considerable pace over the forecast period.
Ultrasound-guided breast biopsy also has certain aspects that impede sales in the market. The ultrasound-guided breast biopsy is known to carry a risk of bleeding that forms hematoma because of which consumers might reject this method of biopsy. This in turn hampers the growth in the ultrasound-guided breast biopsy market.
Furthermore, other factors such as discomfort experienced by patients during biopsy and the cost of an ultrasound machine might also impede the growth in ultrasound-guided breast biopsy market over the forecast period.
The American Cancer Society’s estimates for the year 2022 states that there will be 287,850 new cases of breast cancer, with 43,250 deaths. This rising prevalence of breast cancer along with an increasingly alert population may increase the demand for ultrasound-guided breast biopsy in North America.
Thus, ultrasound-guided breast biopsy market in North America is expected to exhibit a significant growth rate for the forecast period. Advancing technologies, high investments in the healthcare sector, and increasing production of new and improved imaging technologies will augment sales in the ultrasound-guided breast biopsy market in North America.
Increasing awareness regarding early diagnosis and treatment of breast cancer among individuals across Asia Pacific is expected to create opportunities for growth in the market. Owing to rising amount of campaigns about breast cancer, majority of the population is aware about diagnosis and treatment methods for breast cancer. This is expected to boost the Asia Pacific ultrasound-guided breast biopsy market over the forecast period.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Leading players operating in the global ultrasound-guided breast biopsy market include Hologic, Inc., Medsurge Ind Private Limited among others.
Key companies in the market are engaged in developing their portfolio of breast biopsy products and accessories. The focus is also on contracts and partnerships to launch insight driven products, product commercialization and pipeline development in order to strengthen market position.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 8% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Million and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
Procedure, End User, Region |
| Countries Covered |
North America (USA, Canada), Latin America (Mexico, Brazil), Western Europe (Germany, Italy, France, UK, Spain, Nordic countries, Belgium, Netherlands, Luxembourg), Eastern Europe (Russia, Poland), Asia-Pacific Excluding Japan(China, India, ASEAN, Australia & New Zealand), Japan, Middle East and Africa (GCC Countries, South Africa, North Africa) |
| Key Companies Profiled | Hologic Inc; Medsurge Ind Private Limited |
| Customization | Available Upon Request |
North America is set to lead ultrasound-guided breast biopsy market growth over the forecast period.
Hologic Inc. and Medsurge Ind Private Limited are the two key players in the ultrasound-guided breast biopsy market.
The global ultrasound-guided breast biopsy market is estimated to reach USD 720 Million in 2022.
| Estimated Size, 2025 | USD 2.47 billion |
|---|---|
| Projected Size, 2035 | USD 4.21 billion |
| Value-based CAGR (2025 to 2035) | 5.5% |
| Market Valuation (2023) | USD 1.95 billion |
|---|---|
| Market Valuation (2033) | USD 7.23 billion |
| Market CAGR (2023 to 2033) | 14% |
| Market value (2023) | USD 777.29 million |
|---|---|
| Market CAGR (2023 to 2033) | 6.1% |
| Market Value (2033) | USD 1,405.2 million |
Explore Therapeutic Device Insights
View Reports
Ultrasound-Guided Breast Biopsy Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
